Current treatment options for endometrial cancer (Q35843726)

10 August 2017

1 reference

title

Current treatment options for endometrial cancer (English)

1 reference

10 August 2017

Alessandro D Santin

1

1 reference

10 August 2017

Stefania Bellone

2

1 reference

10 August 2017

Timothy J O'Brien

3

1 reference

10 August 2017

Sergio Pecorelli

4

1 reference

10 August 2017

Martin J Cannon

5

1 reference

10 August 2017

Juan J Roman

6

1 reference

10 August 2017

1 August 2004

1 reference

Expert Review of Anticancer Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

4

1 reference

10 August 2017

679-689

1 reference

The justification for a surgical staging system in endometrial carcinoma

10 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

Inefficacy of immediate node dissection in stage 1 melanoma of the limbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

The Role of Adjuvant Radiotherapy in Carcinoma of the Endometrium—Results in 550 Patients with Pathologic Stage I Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.4.679

21 January 2018

Identifiers

DOI

10.1586/14737140.4.4.679

1 reference

10 August 2017

1 reference